MEDX ... anybody following? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following?

MEDX 31.18

-0.3%

9:30 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (2221)	3/21/2011 5:58:22 PM
From: scaram(o)uche	of 2240

finance.yahoo.com Phase III Study of Investigational Compound Ipilimumab Achieves Primary Endpoint of Improvement in Overall Survival in Previously-Untreated Patients with Metastatic Melanoma PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY - News) today announced that a clinical trial -- known as study 024 -- of its investigational compound ipilimumab has met the primary endpoint of improving overall survival in previously-untreated patients with metastatic melanoma. Study 024 was designed to assess overall survival in unresectable stage III or stage IV melanoma patients who have not received prior therapy. The study compares ipilimumab 10mg/kg in combination with chemotherapy (dacarbazine) vs. chemotherapy alone. An abstract of the 024 data will be submitted to the American Society of Clinical Oncology for potential presentation at the Annual Meeting in June of this year. A regulatory filing for ipilimumab, based on a study known as 020, is currently under review by the U.S. Food and Drug Administration and other health authorities worldwide. The filings are based on study 020, which assessed overall survival in previously-treated unresectable stage III or stage IV melanoma patients. Study 020 compared ipilimumab 3 mg/kg + gp100 vaccine vs. gp100 vaccine alone and ipilimumab along vs. gp100 vaccine alone. The PDUFA date for the U.S. filing is March 26, 2011. Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit www.bms.com or follow us on Twitter at twitter.com. Contact: Bristol-Myers Squibb CompanyMedia:Tracy Furey, 609-252-3208tracy.furey@bms.comorInvestors:John Elicker, 609-252-4611john.elicker@bms.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next